Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.33

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $19.33.

Several research analysts have recently issued reports on the company. StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, April 6th. JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Thursday, February 8th.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $13.44 on Friday. The business has a fifty day moving average price of $14.84 and a 200 day moving average price of $11.78. Enanta Pharmaceuticals has a fifty-two week low of $8.08 and a fifty-two week high of $37.75. The stock has a market capitalization of $284.39 million, a price-to-earnings ratio of -2.05 and a beta of 0.47.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.18) by ($0.40). The firm had revenue of $18.00 million during the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. On average, equities analysts expect that Enanta Pharmaceuticals will post -4.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its stake in shares of Enanta Pharmaceuticals by 417.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 2,281 shares during the period. Clearstead Advisors LLC bought a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at approximately $57,000. Quantbot Technologies LP boosted its stake in shares of Enanta Pharmaceuticals by 2,300.0% in the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,900 shares during the period. Sherbrooke Park Advisers LLC bought a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at approximately $113,000. Finally, Laurion Capital Management LP bought a new stake in shares of Enanta Pharmaceuticals in the third quarter valued at approximately $126,000. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.